Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors: An analysis of DNA content (Ploidy), cellular proliferation, and p53 expression

Arie Perry, Robert Brian Jenkins, Judith R. O'Fallon, Paul L. Schaefer, David W. Kimmel, Michelle R. Mahoney, Bernd W. Scheithauer, Sandra M. Smith, Eunice M. Hill, Thomas J. Sebo, Ralph Levitt, James Krook, Loren K. Tschetter, Roscoe F. Morton, Jan Craig Buckner

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

BACKGROUND. The biologic behavior of anaplastic (World Health Organization Grade III) astrocytomas and oligoastrocytomas is highly variable, ranging from rapid progression to prolonged survival. It is difficult to predict the outcome of an individual patient based on morphology alone. METHODS. To determine the prognostic value of commonly used clinicopathologic markers, we reviewed our experience with 85 similarly treated patients enrolled in 3 North Central Cancer Treatment Group high grade glioma protocols. The pathology was comprised exclusively of primary anaplastic astrocytic tumors (66 astrocytomas and 19 oligoastrocytomas). Variables examined included patient age, morphologic type, preoperative performance score, extent of surgery, solitary versus multiple mitoses, DNA flow cytometric and image morphometric parameters, and expression of proliferating cell nuclear antigen, MIB-1, and p53 expression. RESULTS. The study was comprised of 48 men and 37 women ranging in age from 14-79 years (median age, 47 years). Overall survival ranged from <1 month to >12 years (median, 21.6 months). Statistical analyses revealed that age accounted for the majority of this extensive variability in survival. The median survival times were 65.5 months, 22.1 months, and 4.4 months, respectively, for the groups <40 years, 40-59 years, and ≥60 years, respectively (P < 0.0001). On univariate analyses, aneuploidy by flow cytometry and a low performance score also predicted a better survival (P values of 0.04 and 0.009, respectively). Statistical trends predicting a better survival were observed for patients with a solitary mitosis and p53 immunopositivity. However, only patient age remained significant in multivariate models. CONCLUSIONS. In a small but relatively uniformly treated cohort of patients with anaplastic astrocytomas and oligoastrocytomas, patient age was associated strongly and inversely with overall survival. Once patient age was taken into account, the clinical and pathologic markers tested appeared to be of limited prognostic value.

Original languageEnglish (US)
Pages (from-to)672-683
Number of pages12
JournalCancer
Volume86
Issue number4
DOIs
StatePublished - Aug 15 1999

Fingerprint

Ploidies
Cell Proliferation
DNA
Survival
Neoplasms
Astrocytoma
Mitosis
Proliferating Cell Nuclear Antigen
Aneuploidy
Glioma
Flow Cytometry
Biomarkers
Pathology

Keywords

  • Astrocytoma
  • Flow cytometry
  • Glioma
  • Immunohistochemistry
  • Ki-67
  • p53 protein
  • Prognosis
  • Proliferating cell nuclear antigen
  • Proliferation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors : An analysis of DNA content (Ploidy), cellular proliferation, and p53 expression. / Perry, Arie; Jenkins, Robert Brian; O'Fallon, Judith R.; Schaefer, Paul L.; Kimmel, David W.; Mahoney, Michelle R.; Scheithauer, Bernd W.; Smith, Sandra M.; Hill, Eunice M.; Sebo, Thomas J.; Levitt, Ralph; Krook, James; Tschetter, Loren K.; Morton, Roscoe F.; Buckner, Jan Craig.

In: Cancer, Vol. 86, No. 4, 15.08.1999, p. 672-683.

Research output: Contribution to journalArticle

Perry, A, Jenkins, RB, O'Fallon, JR, Schaefer, PL, Kimmel, DW, Mahoney, MR, Scheithauer, BW, Smith, SM, Hill, EM, Sebo, TJ, Levitt, R, Krook, J, Tschetter, LK, Morton, RF & Buckner, JC 1999, 'Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors: An analysis of DNA content (Ploidy), cellular proliferation, and p53 expression', Cancer, vol. 86, no. 4, pp. 672-683. https://doi.org/10.1002/(SICI)1097-0142(19990815)86:4<672::AID-CNCR17>3.0.CO;2-G
Perry, Arie ; Jenkins, Robert Brian ; O'Fallon, Judith R. ; Schaefer, Paul L. ; Kimmel, David W. ; Mahoney, Michelle R. ; Scheithauer, Bernd W. ; Smith, Sandra M. ; Hill, Eunice M. ; Sebo, Thomas J. ; Levitt, Ralph ; Krook, James ; Tschetter, Loren K. ; Morton, Roscoe F. ; Buckner, Jan Craig. / Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors : An analysis of DNA content (Ploidy), cellular proliferation, and p53 expression. In: Cancer. 1999 ; Vol. 86, No. 4. pp. 672-683.
@article{f2e4b28282c64ab79960103175f6fb76,
title = "Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors: An analysis of DNA content (Ploidy), cellular proliferation, and p53 expression",
abstract = "BACKGROUND. The biologic behavior of anaplastic (World Health Organization Grade III) astrocytomas and oligoastrocytomas is highly variable, ranging from rapid progression to prolonged survival. It is difficult to predict the outcome of an individual patient based on morphology alone. METHODS. To determine the prognostic value of commonly used clinicopathologic markers, we reviewed our experience with 85 similarly treated patients enrolled in 3 North Central Cancer Treatment Group high grade glioma protocols. The pathology was comprised exclusively of primary anaplastic astrocytic tumors (66 astrocytomas and 19 oligoastrocytomas). Variables examined included patient age, morphologic type, preoperative performance score, extent of surgery, solitary versus multiple mitoses, DNA flow cytometric and image morphometric parameters, and expression of proliferating cell nuclear antigen, MIB-1, and p53 expression. RESULTS. The study was comprised of 48 men and 37 women ranging in age from 14-79 years (median age, 47 years). Overall survival ranged from <1 month to >12 years (median, 21.6 months). Statistical analyses revealed that age accounted for the majority of this extensive variability in survival. The median survival times were 65.5 months, 22.1 months, and 4.4 months, respectively, for the groups <40 years, 40-59 years, and ≥60 years, respectively (P < 0.0001). On univariate analyses, aneuploidy by flow cytometry and a low performance score also predicted a better survival (P values of 0.04 and 0.009, respectively). Statistical trends predicting a better survival were observed for patients with a solitary mitosis and p53 immunopositivity. However, only patient age remained significant in multivariate models. CONCLUSIONS. In a small but relatively uniformly treated cohort of patients with anaplastic astrocytomas and oligoastrocytomas, patient age was associated strongly and inversely with overall survival. Once patient age was taken into account, the clinical and pathologic markers tested appeared to be of limited prognostic value.",
keywords = "Astrocytoma, Flow cytometry, Glioma, Immunohistochemistry, Ki-67, p53 protein, Prognosis, Proliferating cell nuclear antigen, Proliferation",
author = "Arie Perry and Jenkins, {Robert Brian} and O'Fallon, {Judith R.} and Schaefer, {Paul L.} and Kimmel, {David W.} and Mahoney, {Michelle R.} and Scheithauer, {Bernd W.} and Smith, {Sandra M.} and Hill, {Eunice M.} and Sebo, {Thomas J.} and Ralph Levitt and James Krook and Tschetter, {Loren K.} and Morton, {Roscoe F.} and Buckner, {Jan Craig}",
year = "1999",
month = "8",
day = "15",
doi = "10.1002/(SICI)1097-0142(19990815)86:4<672::AID-CNCR17>3.0.CO;2-G",
language = "English (US)",
volume = "86",
pages = "672--683",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors

T2 - An analysis of DNA content (Ploidy), cellular proliferation, and p53 expression

AU - Perry, Arie

AU - Jenkins, Robert Brian

AU - O'Fallon, Judith R.

AU - Schaefer, Paul L.

AU - Kimmel, David W.

AU - Mahoney, Michelle R.

AU - Scheithauer, Bernd W.

AU - Smith, Sandra M.

AU - Hill, Eunice M.

AU - Sebo, Thomas J.

AU - Levitt, Ralph

AU - Krook, James

AU - Tschetter, Loren K.

AU - Morton, Roscoe F.

AU - Buckner, Jan Craig

PY - 1999/8/15

Y1 - 1999/8/15

N2 - BACKGROUND. The biologic behavior of anaplastic (World Health Organization Grade III) astrocytomas and oligoastrocytomas is highly variable, ranging from rapid progression to prolonged survival. It is difficult to predict the outcome of an individual patient based on morphology alone. METHODS. To determine the prognostic value of commonly used clinicopathologic markers, we reviewed our experience with 85 similarly treated patients enrolled in 3 North Central Cancer Treatment Group high grade glioma protocols. The pathology was comprised exclusively of primary anaplastic astrocytic tumors (66 astrocytomas and 19 oligoastrocytomas). Variables examined included patient age, morphologic type, preoperative performance score, extent of surgery, solitary versus multiple mitoses, DNA flow cytometric and image morphometric parameters, and expression of proliferating cell nuclear antigen, MIB-1, and p53 expression. RESULTS. The study was comprised of 48 men and 37 women ranging in age from 14-79 years (median age, 47 years). Overall survival ranged from <1 month to >12 years (median, 21.6 months). Statistical analyses revealed that age accounted for the majority of this extensive variability in survival. The median survival times were 65.5 months, 22.1 months, and 4.4 months, respectively, for the groups <40 years, 40-59 years, and ≥60 years, respectively (P < 0.0001). On univariate analyses, aneuploidy by flow cytometry and a low performance score also predicted a better survival (P values of 0.04 and 0.009, respectively). Statistical trends predicting a better survival were observed for patients with a solitary mitosis and p53 immunopositivity. However, only patient age remained significant in multivariate models. CONCLUSIONS. In a small but relatively uniformly treated cohort of patients with anaplastic astrocytomas and oligoastrocytomas, patient age was associated strongly and inversely with overall survival. Once patient age was taken into account, the clinical and pathologic markers tested appeared to be of limited prognostic value.

AB - BACKGROUND. The biologic behavior of anaplastic (World Health Organization Grade III) astrocytomas and oligoastrocytomas is highly variable, ranging from rapid progression to prolonged survival. It is difficult to predict the outcome of an individual patient based on morphology alone. METHODS. To determine the prognostic value of commonly used clinicopathologic markers, we reviewed our experience with 85 similarly treated patients enrolled in 3 North Central Cancer Treatment Group high grade glioma protocols. The pathology was comprised exclusively of primary anaplastic astrocytic tumors (66 astrocytomas and 19 oligoastrocytomas). Variables examined included patient age, morphologic type, preoperative performance score, extent of surgery, solitary versus multiple mitoses, DNA flow cytometric and image morphometric parameters, and expression of proliferating cell nuclear antigen, MIB-1, and p53 expression. RESULTS. The study was comprised of 48 men and 37 women ranging in age from 14-79 years (median age, 47 years). Overall survival ranged from <1 month to >12 years (median, 21.6 months). Statistical analyses revealed that age accounted for the majority of this extensive variability in survival. The median survival times were 65.5 months, 22.1 months, and 4.4 months, respectively, for the groups <40 years, 40-59 years, and ≥60 years, respectively (P < 0.0001). On univariate analyses, aneuploidy by flow cytometry and a low performance score also predicted a better survival (P values of 0.04 and 0.009, respectively). Statistical trends predicting a better survival were observed for patients with a solitary mitosis and p53 immunopositivity. However, only patient age remained significant in multivariate models. CONCLUSIONS. In a small but relatively uniformly treated cohort of patients with anaplastic astrocytomas and oligoastrocytomas, patient age was associated strongly and inversely with overall survival. Once patient age was taken into account, the clinical and pathologic markers tested appeared to be of limited prognostic value.

KW - Astrocytoma

KW - Flow cytometry

KW - Glioma

KW - Immunohistochemistry

KW - Ki-67

KW - p53 protein

KW - Prognosis

KW - Proliferating cell nuclear antigen

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=0033567041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033567041&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990815)86:4<672::AID-CNCR17>3.0.CO;2-G

DO - 10.1002/(SICI)1097-0142(19990815)86:4<672::AID-CNCR17>3.0.CO;2-G

M3 - Article

C2 - 10440696

AN - SCOPUS:0033567041

VL - 86

SP - 672

EP - 683

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -